Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06855498

PHASE3

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Sponsor: Incyte Corporation

View on ClinicalTrials.gov

Summary

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Official title: A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

600

Start Date

2025-02-28

Completion Date

2028-02-28

Last Updated

2026-10-30

Healthy Volunteers

Conditions

Hidradenitis Suppurativa (HS)

Interventions

DRUG

povorcitinib

Study drug will be taken orally as defined by the protocol.

Inclusion Criteria: * Ability to comprehend and willingness to sign a written ICF for the study. * Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment. * Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator. * Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements. * Willingness to avoid pregnancy or fathering children as defined in the protocol. * Willingness and ability to comply with the study Protocol and procedures. Exclusion Criteria: * Had been permanently discontinued from study treatment during the parent study. * Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study. * Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study: * Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab). * Live, attenuated vaccine. * Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug. * Women who are pregnant (or who are considering pregnancy) or breastfeeding. * Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class. * Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study. * Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data. Other protocol-defined Inclusion/Exclusion Criteria may apply.

Locations (306)

Investigative Site US106

Birmingham, Alabama, United States

Investigative Site US086

Birmingham, Alabama, United States

Investigative Site US141

Birmingham, Alabama, United States

Investigative Site US098

Montgomery, Alabama, United States

Investigative Site US004

Phoenix, Arizona, United States

Investigative Site US142

Phoenix, Arizona, United States

Investigative Site US115

Tucson, Arizona, United States

Investigative Site US076

Fountain Valley, California, United States

Investigative Site US077

Fremont, California, United States

Investigative Site US071

Huntington Beach, California, United States

Investigative Site US097

Irvine, California, United States

Investigative Site US020

Laguna Niguel, California, United States

Investigative Site US036

Los Angeles, California, United States

Investigative Site US095

Los Angeles, California, United States

Investigative Site US067

Los Angeles, California, United States

Investigative Site US060

Northridge, California, United States

Investigative Site US037

Oakland, California, United States

Investigative Site US089

Santa Monica, California, United States

Investigative Site US080

Sherman Oaks, California, United States

Investigative Site US104

Sunnyvale, California, United States

Investigative Site US002

Boca Raton, Florida, United States

Investigative Site US084

Coral Gables, Florida, United States

Investigative Site US017

Hialeah, Florida, United States

Investigative Site US019

Hollywood, Florida, United States

Investigative Site US062

Miami, Florida, United States

Investigative Site US015

Miami, Florida, United States

Investigative Site US059

Miami, Florida, United States

Investigative Site US072

Miami Lakes, Florida, United States

Investigative Site US079

Miami Lakes, Florida, United States

Investigative Site US023

North Miami Beach, Florida, United States

Investigative Site US029

Ocala, Florida, United States

Investigative Site US035

Tampa, Florida, United States

Investigative Site US133

Tampa, Florida, United States

Investigative Site US005

Tampa, Florida, United States

Investigative Site US001

Tampa, Florida, United States

Investigative Site US066

West Palm Beach, Florida, United States

Investigative Site US070

West Palm Beach, Florida, United States

Investigative Site US102

Cumming, Georgia, United States

Investigative Site US051

Marietta, Georgia, United States

Investigative Site US103

Sandy Springs, Georgia, United States

Investigative Site US100

Stonecrest, Georgia, United States

Investigative Site US125

Chicago, Illinois, United States

Investigative Site US093

Chicago, Illinois, United States

Investigative Site US136

Skokie, Illinois, United States

Investigative Site US039

West Dundee, Illinois, United States

Investigative Site US108

Indianapolis, Indiana, United States

Investigative Site US008

Indianapolis, Indiana, United States

Investigative Site US064

West Lafayette, Indiana, United States

Investigative Site US012

Baton Rouge, Louisiana, United States

Investigative Site US057

New Orleans, Louisiana, United States

Investigative Site US038

Baltimore, Maryland, United States

Investigative Site US099

Glenn Dale, Maryland, United States

Investigative Site US101

Rockville, Maryland, United States

Investigative Site US030

Boston, Massachusetts, United States

Investigative Site US048

Brighton, Massachusetts, United States

Investigative Site US061

Ann Arbor, Michigan, United States

Investigative Site US114

Auburn Hills, Michigan, United States

Investigative Site US140

Detroit, Michigan, United States

Investigative Site US120

Detroit, Michigan, United States

Investigative Site US091

Troy, Michigan, United States

Investigative Site US042

Waterford, Michigan, United States

Investigative Site US011

Minneapolis, Minnesota, United States

Investigative Site US088

Saint Joseph, Missouri, United States

Investigative Site US016

St Louis, Missouri, United States

Investigative Site US135

Missoula, Montana, United States

Investigative Site US007

Portsmouth, New Hampshire, United States

Investigative Site US118

Albuquerque, New Mexico, United States

Investigative Site US082

East Syracuse, New York, United States

Investigative Site US034

New York, New York, United States

Investigative Site US081

New York, New York, United States

Investigative Site US065

New York, New York, United States

Investigative Site US075

New York, New York, United States

Investigative Site US050

Rochester, New York, United States

Investigative Site US031

Chapel Hill, North Carolina, United States

Investigative Site US028

Bexley, Ohio, United States

Investigative Site US025

Cincinnati, Ohio, United States

Investigative Site US073

Columbus, Ohio, United States

Investigative Site US117

Dublin, Ohio, United States

Investigative Site US085

Oklahoma City, Oklahoma, United States

Investigative Site US138

Danville, Pennsylvania, United States

Investigative Site US074

Philadelphia, Pennsylvania, United States

Investigative Site US069

Plymouth Meeting, Pennsylvania, United States

Investigative Site US021

Bellaire, Texas, United States

Investigative Site US078

Dallas, Texas, United States

Investigative Site US010

Dallas, Texas, United States

Investigative Site US109

Plano, Texas, United States

Investigative Site US083

San Antonio, Texas, United States

Investigative Site US068

Webster, Texas, United States

Investigative Site US063

South Jordan, Utah, United States

Investigative Site US027

Norfolk, Virginia, United States

Investigative Site US094

Richmond, Virginia, United States

Investigative Site US132

Mill Creek, Washington, United States

Investigative Site US092

Seattle, Washington, United States

Investigative Site US003

Spokane, Washington, United States

Investigative Site AR005

Buenos Aires, Argentina

Investigative Site AR002

Buenos Aires, Argentina

Investigative Site AR004

Mar del Plata, Argentina

Investigative Site AR003

Rosario, Argentina

Investigative Site AR001

San Miguel de Tucumán, Argentina

Investigative Site AU001

Charleston, New South Wales, Australia

And 206 more locations on ClinicalTrials.gov

Clinical Research Directory

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (306)